World Journal of Gastroenterology

BACKGROUND Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Tyrosine kinase inhibitors, such as imatinib, have been used as first-line therapy for the treatment of GISTs. Although these drugs have achieved considerable efficacy in some patients, reports of resistance and recurrence have emerged. Extracellular signal-regulated kinase 1/2 (ERK1/2) protein, as a member of the mitogen-activated protein kinase (MAPK) family, is a core molecule of this signaling pathway. Nowadays, research reports on the important clinical and prognostic value of phosphorylated-ERK (P-ERK) and phosphorylated-MAPK/ERK kinase (P-MEK) proteins closely related to raf kinase inhibitor protein (RKIP) have gradually emerged in digestive tract tumors such as gastric cancer, colon cancer, and pancreatic cancer. However, literature on the expression of these downstream proteins combined with RKIP in GIST is scarce. This study will focus on this aspect and search for answers to the problem.

[1]  Yingchun Zhu,et al.  Emerging Noninvasive Neuromodulation Methods for Functional Gastrointestinal Diseases , 2022, Journal of translational internal medicine.

[2]  Huiyan Jiang,et al.  Basic Pancreatic Lesions: Radiologic-pathologic Correlation , 2022, Journal of translational internal medicine.

[3]  M. Rosner,et al.  Harnessing RKIP to Combat Heart Disease and Cancer , 2022, Cancers.

[4]  I. Sjaastad,et al.  MSK-Mediated Phosphorylation of Histone H3 Ser28 Couples MAPK Signalling with Early Gene Induction and Cardiac Hypertrophy , 2022, Cells.

[5]  Keran Sun,et al.  Dawning precision treatment for gastric cancer: The latest biomarkers , 2021, Journal of translational internal medicine.

[6]  C. M.,et al.  SELNET clinical practice guidelines for soft tissue sarcoma and GIST. , 2021, Cancer treatment reviews.

[7]  T. Takasaki,et al.  ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer , 2021, Cells.

[8]  F. Rieux-Laucat,et al.  RASopathies: From germline mutations to somatic and multigenic diseases , 2021, Biomedical journal.

[9]  Federica Accornero,et al.  ERK1/2: An Integrator of Signals That Alters Cardiac Homeostasis and Growth , 2021, Biology.

[10]  Yidan Lu,et al.  Chloroquine Combined with Imatinib Overcomes Imatinib Resistance in Gastrointestinal Stromal Tumors by Inhibiting Autophagy via the MAPK/ERK Pathway , 2020, OncoTargets and therapy.

[11]  Ni Zeng,et al.  Role of extracellular signal-regulated kinase 1/2 signaling underlying cardiac hypertrophy , 2020, Cardiology journal.

[12]  K. Lorenz,et al.  The N-termini of GRK2 and GRK3 simulate the stimulating effects of RKIP on β-adrenoceptors. , 2019, Biochemical and biophysical research communications.

[13]  P. Nilsson,et al.  Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment , 2019, PloS one.

[14]  P. Comoglio,et al.  ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy , 2019, International journal of molecular sciences.

[15]  E. Petricoin,et al.  Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer , 2019, Nature Medicine.

[16]  J. Yu,et al.  A new nomogram for recurrence-free survival prediction of gastrointestinal stromal tumors: Comparison with current risk classification methods. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  Q. Wang,et al.  Clinical and prognostic significance of Raf kinase inhibitory protein expression in gastrointestinal stromal tumors , 2018, World journal of gastroenterology.

[18]  Haoming Lin,et al.  KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK–ERK pathway in pancreatic cancer , 2018, International journal of cancer.

[19]  Hermann Schindelin,et al.  Conserved salt-bridge competition triggered by phosphorylation regulates the protein interactome , 2017, Proceedings of the National Academy of Sciences.

[20]  L. Gesualdo,et al.  Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma , 2017, Oncotarget.

[21]  Cheng-ling Zhao,et al.  Reduced RKIP expression levels are associated with frequent non-small cell lung cancer metastasis and STAT3 phosphorylation and activation , 2017, Oncology letters.

[22]  Li Yuan,et al.  Reduced RKIP enhances nasopharyngeal carcinoma radioresistance by increasing ERK and AKT activity , 2016, Oncotarget.

[23]  Q. Fan,et al.  RKIP suppresses the proliferation and invasion ofchoriocarcinoma cells through inhibiting the MAPK signaling pathway. , 2015, International journal of clinical and experimental medicine.

[24]  A. Ba-Ssalamah,et al.  Downregulation of phosphatidylethanolamine binding protein 1 associates with clinical risk factors in gastrointestinal stromal tumors, but not with activation of the RAF-1-MEK-ETV1 pathway. , 2013, Cancer letters.

[25]  K. Kojima,et al.  Prognostic value of RKIP and p-ERK in gastric cancer , 2012, Journal of experimental & clinical cancer research : CR.

[26]  R. Reis,et al.  Loss of RKIP expression is associated with poor survival in GISTs , 2009, Virchows Archiv.

[27]  D. McElheny,et al.  Raf Kinase Inhibitory Protein Function Is Regulated via a Flexible Pocket and Novel Phosphorylation-Dependent Mechanism , 2008, Molecular and Cellular Biology.

[28]  W. Kolch,et al.  Snail is a repressor of RKIP transcription in metastatic prostate cancer cells , 2008, Oncogene.

[29]  J. Desai,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[30]  K. Lorenz,et al.  Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2 , 2003, Nature.

[31]  A. Vercoutter-Edouart,et al.  FGF signals for cell proliferation and migration through different pathways. , 2000, Cytokine & growth factor reviews.

[32]  G. Tzivion,et al.  Raf-1/MEK/MAPK Pathway Is Necessary for the G2/M Transition Induced by Nocodazole* , 2000, The Journal of Biological Chemistry.

[33]  W. Kolch,et al.  Mechanism of Suppression of the Raf/MEK/Extracellular Signal-Regulated Kinase Pathway by the Raf Kinase Inhibitor Protein , 2000, Molecular and Cellular Biology.

[34]  J. McIntosh,et al.  Activation of the MKK/ERK Pathway during Somatic Cell Mitosis: Direct Interactions of Active ERK with Kinetochores and Regulation of the Mitotic 3F3/2 Phosphoantigen , 1998, The Journal of cell biology.

[35]  A. Catling,et al.  Active MAP Kinase in Mitosis: Localization at Kinetochores and Association with the Motor Protein CENP-E , 1998, The Journal of cell biology.

[36]  K. Moelling,et al.  Mitotic Raf-1 Is Stimulated Independently of Ras and Is Active in the Cytoplasm* , 1998, The Journal of Biological Chemistry.

[37]  M. Rosner,et al.  Raf kinase inhibitory protein (RKIP) as a metastasis suppressor: regulation of signaling networks in cancer. , 2014, Critical reviews in oncogenesis.

[38]  Fan Heng.  Mitogen activated Protein Kinase (MAPK) Signaling Pathways: State of the art , 2002 .